Chemical Nameemicizumab
Dosage FormInjection (subcutaneous; 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL, 150 mg/mL)
Drug ClassMonoclonal antibodies
CompanyGenentech Inc.
Approval Year2017


  • To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Hemlibra (emicizumab) Prescribing Information2018Genentech, Inc.